AMAndres Morales La Madrid

Andres Morales La Madrid

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Andres Morales La Madrid has a total of 93 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Achieving Language Justice in Pediatric Hematology‐Oncology: A Multinational Perspective for Language‐Concordant Equitable Patient‐ and Family‐Centered Care and Research Inclusion

    by Jenny Ruiz, Joanna M. Robles, Luisanna M. Sánchez, Alisa Khan, Amy D. Lu, Stacey Marjerrison, Andres Morales La Madrid, Paula Aristizabal

    Language‐discordant healthcare encounters—when the patient/caregiver and clinician are not able to communicate directly in the patient's/caregiver's preferred language—are associated with worse quality of care, increased adverse events, and research exclusion. Here, we describe the current state of language justice in clinical practice and research in the United States, Canada, and Spain, discuss the role of social determinants of health and language in patient safety and health outcomes, and review an example of culturally and linguistically concordant interventions to increase research participation. We close with practical and global strategies to increase multilingual research participation and to provide equitable patient‐ and family‐centered care in pediatric hematology‐oncology.


  • Open Access

    Patient Acceptability of the First Integrative Pediatric Oncology Unit in Spain—The Pediatric Cancer Center Barcelona Experience: A Retrospective Study

    by Esther Martínez García, Cristina López de San Roman Fernández, M. Betina Nishishinya Aquino, Sara Pérez-Jaume, Carles Fernández-Jané, Ofelia Cruz Martínez, Andrés Morales La Madrid

    Background/Objectives: Pediatric cancer patients and their families are increasingly combining conventional treatment with complementary therapies. These therapies are not covered by most public healthcare systems, and Spain is not an exception. To address this need, the Pediatric Cancer Center Barcelona, at the Hospital Sant Joan de Déu (Spain), established the first integrative pediatric oncology unit in 2019. The objective of this study is to describe the feasibility of implementing a pediatric integrative oncology unit, in terms of the acceptance of the interventions, as well as to present initial data on the care activities; Methods: This is a retrospective single-center study, conducted in the Pediatric Cancer Center Barcelona, at the Hospital Sant Joan de Déu. Data from patients during a two-year period were collected by reviewing medical records in a pseudonymous manner; Results: From 1 September 2019 to 30 September 2021, the unit was visited by 433 patients. The median age of patients was 9 years [range 0–34 years], with 266 boys (61.4%) and 167 girls (38.6%). Of these patients, 90.1% were in active treatment, 7.6% were survivors, and 2.3% were at the end of life. Acupuncture was recommended to 227 patients, with a 94.7% acceptance rate. Aromatherapy was recommended to 114 patients, with a 100% acceptance. The reflexology team visited 129 patients, delivering a total of 414 sessions, with a 96.1% acceptance.; Conclusions: The findings of our study support the feasibility of implementing an Integrative Pediatric Oncology Unit within a patient-centered care model in a comprehensive pediatric cancer center. The high acceptance rates of various complementary therapies highlight their potential role in enhancing supportive care for pediatric oncology patients.


  • Open Access

    Del glioma intrínseco difuso de protuberancia al glioma difuso de línea media H3K27M-alterado: ¿cuál ha sido el papel de la biopsia estereotáctica?

    by Revista Argentina de Neurocirugia Ranc, María Victoria Becerra Castro, Mariana Alamar Abril, Diego Culebras Palau, Santiago Candela Cantó, Andrés Morales La Madrid, José Hinojosa Mena-Bernal

    Introducción: la biopsia estereotáxica en el tumor difuso de protuberancia ha demostrado ser una técnica factible, con alta rentabilidad diagnóstica y baja morbilidad neurológica. Además, ha abierto las puertas a nuevos enfoques terapéuticos basados en la medicina individualizada y los ensayos clínicos, en una enfermedad en la que, actualmente, no existe tratamiento curativo y cuya supervivencia es completamente infausta. Sin embargo, durante años, el papel de este procedimiento quirúrgico en el manejo diagnóstico y terapéutico del paciente pediátrico con glioma pontino intrínseco difuso (GPID) ha sido cuestionado y controvertido. Objetivos: realizar una revisión histórica sobre la percepción quirúrgica e indicación de la biopsia estereotáctica en el GPID, así como su contribución al conocimiento y comprensión de su compleja biología molecular y, consecuentemente, su repercusión en las nuevas terapias. Material y métodos: se describen las características generales y de diagnóstico habitual del GPID. Posteriormente, se analizan las limitaciones y consecuencias del diagnóstico clásico, así como su repercusión en el tratamiento de este tipo de tumor. Resultados: se realiza una viñeta histórica sobre el rol de la biopsia estereotáctica en los tumores de tronco y, en particular, en el GPID, junto con su repercusión en el conocimiento, su biología molecular y avances terapéuticos. Conclusiones: la biopsia estereotáctica en el tumor difuso de protuberancia es un procedimiento factible con una baja morbi-mortalidad y alta rentabilidad diagnóstica: se aconseja llevarla a cabo en centros médicos experimentados de referencia en neuro-oncología pediátrica.

  • Open Access

    Brain stem tumors in children less than 3 months: Clinical and radiologic findings of a rare disease

    by Danai Papangelopoulou, Brigitte Bison, Lars Behrens, Simon Bailey, Marc Ansari, Karoline Ehlert, Ofelia Cruz Martinez, Christof M. Kramm, Andres Morales La Madrid, Andre O. von Bueren

    Purpose: Brain stem tumors in children < 3 months at diagnosis are extremely rare. Our aim is to study a retrospective cohort to improve the understanding of the disease course and guide patient management. Methods: This is a multicenter retrospective analysis across the European Society for Pediatric Oncology SIOP-E HGG/DIPG Working Group linked centers, including patients with a brainstem tumor diagnosed between 2009 and 2020 and aged < 3 months at diagnosis. Clinical data were collected, and imaging characteristics were analyzed blindly and independently by two neuroradiologists. Results: Five cases were identified. No patient received any therapy. The epicenter of two tumors was in the medulla oblongata alone and in the medulla oblongata and the pons in three. For patients with tumor in equal parts in the medulla oblongata and the pons (n = 3), the extension at diagnosis involved the spinal cord; for the two patients with the tumor epicenter in the medulla oblongata alone (n = 2), the extension at diagnosis included the pons (n = 2) and the spinal cord (n = 1). Biopsy was performed in one patient identifying a pilocytic astrocytoma. Two patients died. In one patient, autopsy revealed a high-grade glioma (case 3). Three survivors showed either spontaneous tumor regression (n = 2) or stable disease (n = 1). Survivors were followed up for 10, 7, and 0.6 years, respectively. One case had the typical imaging characteristics of a dorsal exophytic low-grade glioma. Conclusions: No patient fulfilled the radiologic criteria defining a high-grade glioma. Central neuroradiological review and biopsy may provide useful information regarding the patient management.


  • Open Access

    Supplementary Figures S1-S3 from Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma

    by Diana M. Carvalho, Peter J. Richardson, Nagore Olaciregui, Reda Stankunaite, Cinzia Lavarino, Valeria Molinari, Elizabeth A. Corley, Daniel P. Smith, Ruth Ruddle, Adam Donovan, et al.

  • Seizure control in tumor‐associated epilepsy secondary to BRAF inhibition

    by Marta Perez‐Somarriba, Vicente Santa‐María, Ofelia Cruz, Jordi Muchart, Nagore Gene, Jose Hinojosa Mena‐Bernal, Veronica Gonzalez, Andres Morales La Madrid


  • Open Access

    Follow‐up evaluation of a web‐based pediatric brain tumor board in Latin America

    by Mariel Rosabal‐Obando, Diana S. Osorio, Alvaro Lassaletta, Andrés Morales La Madrid, Ute Bartels, Jonathan L. Finlay, Ibrahim Qaddoumi, Stefan Rutkowski, Martin Mynarek

    Background: Since 2013, pediatric oncologists from Central and South America discuss neuro‐oncology cases with experts from North America and Europe in a web‐based “Latin American Tumor Board” (LATB). Here, we evaluate the feasibility of recommendations rendered by the Board.Methods: An electronic questionnaire was distributed to physicians who had received recommendations between October 2017 and October 2018. Physicians were asked regarding the feasibility of each recommendation given during the LATB discussion. Baseline case characteristics of all presented cases were obtained from anonymized minutes.Results: Of the 142 patients discussed, data on 103 patients from 15 countries were available, corresponding to 283 recommendations. Physicians followed 60% of diagnostic procedural recommendations and 69% of therapeutic recommendations. The most difficult recommendations to follow were genetic and molecular testing, pathology review, chemotherapy, surgery, and molecular targeted therapies. Histological diagnoses changed in eight of 18 cases in which a pathology review was undertaken. Fifty‐four percent of the recommendations that could not be implemented were considered not feasible in the specific context of the patient, while 31% were not implemented due to a decision of the medical staff or the parents (15% not specified). However, 96% of respondents considered the recommendations useful.Conclusion: Recommendations were frequently perceived as useful, and were applicable in the participating institutions. Nevertheless, limitations in availability of diagnostic procedures and treatment modalities affected the feasibility of some recommendations. Tele‐oncology tumor boards offer physicians from low‐ and middle‐income countries access to real‐time, high‐level subspecialist expertise and provide a valuable platform for worldwide information exchange.


  • Craniospinal irradiation as a salvage treatment for metastatic relapsed DIPG

    by Marta Perez‐Somarriba, Vicente Santa‐Maria, Ofelia Cruz, Jordi Muchart, Cinzia Lavarino, Soraya Mico, Andres Morales La Madrid


  • Treatment response of CNS high‐grade neuroepithelial tumors with MN1 alteration

    by Lorena V. Baroni, Carlos Rugilo, Fabiana Lubieniecki, Claudia Sampor, Candela Freytes, Liana Nobre, Jordan R. Hansford, Vajiranee S. Malalasekera, Michal Zapotocky, Andrew Dodgshun, et al.

    Central nervous system high‐grade neuroepithelial tumor with MN1 alteration (CNS HGNET‐MN1) is a rare recently described entity. Fourteen CNS HGNET‐MN1 patients were identified using genome‐wide methylation arrays/RT‐PCR across seven institutions. All patients had surgery (gross total resection: 10; subtotal resection: four) as initial management followed by observation alone in three patients, followed by radiotherapy in eight patients (focal: five; craniospinal: two; CyberKnife: one) and systemic chemotherapy in three patients. Seven patients relapsed; five local and two metastatic, despite adjuvant radiotherapy, of which three died. Treatment of CNS HGNET‐MN1 remains a major treatment challenge despite aggressive surgical resections and upfront radiotherapy, warranting new approaches to this rare malignancy.


  • Sinonasal adenocarcinoma involving the anterior cranial fossa: An exceptional entity in the pediatric population

    by Andrés Morales La Madrid, Mario Hermsen, Antonio Guillén Quesada, Jordi Muchart, Carlota Rovira, Vicente Santa‐María, Ofelia Cruz, José Luis Llorente, Patricia Puerta Roldán